Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease

    ... lenalidomide ), and hypomethylating therapy [HMT ( decitabine and 5-azacytidine)]. All patients will eventually lose their ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Myelodysplastic syndromes: What do hospitalists need to know?

    ... therapy. The addition of azacitidine , decitabine , and lenalidomide to erythropoiesis-stimulating agents ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. An update on the treatment of myelodysplastic syndromes.

    ... hypomethylating agents, azacitidine and decitabine , are approved for intermediate-2- and high-risk MDS. Trial ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.

    ... inhibitors, 5-azacytidine and 5-aza-2'-deoxycytidine or decitabine , represent frontline nonablative treatments, while combinations ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Methylation of the p73 gene in patients with myelodysplastic syndromes: correlations with apoptosis and prognosis

    ... than that in the unmethylated group (p  =  0.094), decitabine treatment restored p73 expression and increased the level of ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes.

    ... methyltransferase inhibitors azacitidine and decitabine . Recently, azacitidine demonstrated the ability to extend ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... and a chromosome 5 alteration. 5- azacitidine and decitabine have activity in higher risk MDS. 5-azacitidine has been shown ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... and a chromosome 5 alteration. 5- Azacitidine and decitabine have activity in higher risk MDS. 5-Azacitidine has been shown ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. Epigenetic therapy in myelodysplastic syndromes.

    ... of epigenetic modifiers, such as azacytidine and decitabine , trying to explain the biologic rationale for their use in this ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... and a chromosome 5 alteration. 5- azacitidine and decitabine have activity in higher risk MDS. 5-azacitidine has been shown ...

    Research Article last updated 07/20/2018 - 5:14pm.